Regeneus (ASX:RGS), a clinical-stage regenerative medicine company, has announced that topical use of Sygenus gel for six weeks in adults with acne was well tolerated and showed a significant effect on the appearance of acne lesions as early as 3 weeks.
Sygenus is an allogeneic cell secretions technology platform that comprises cytokines, growth factors and exosomes from adipose-derived mesenchymal stem cells (MSCs). T
According to the company, these bioactive molecules work to reduce pain and inflammation and encourage accelerated healing and repair.
The tolerance study, performed by RCTS, a dermatology testing company in the US, assessed the tolerability of Sygenus in 33 healthy volunteers with mild to moderate facial acne.
The study endpoints to assess tolerability involved the change in acne lesions over the 6-week period. Sygenus gel was applied topically twice a day throughout the study. No intolerance was observed and there was an overall improvement in the appearance of acne, as early as 3 weeks, said the company.
"Statistically significant reductions in the total number of inflammatory and non-inflammatory acne lesions were noted from baseline to week 6," it said. "Further the acne global severity score showed significant reduction (improvement) at week 6 compared to baseline."
Regeneus has received granted patents in Australia, Europe, China, USA and Japan covering the composition, manufacture and use of the Sygenus technology for the topical treatment of acne. The company also has patent applications for the use of Sygenus for a broad range of other inflammatory skin conditions.